Baseline characteristics of the transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (sAVR) group
| Parameter | TAVI (n=101) | sAVR (n=22) | p Value |
| Age (years) | 81±11 | 71±12 | 0.0004 |
| 82 (IQR 77–86) | 73 (IQR 63–79) | ||
| Gender. female (n/%) | 68/67% | 14/63% | 0.93 |
| Weight (kg) | 75±17 | 70±19 | 0.3 |
| 74 (IQR 62–85) | 72 (IQR 65–85) | ||
| Height (cm) | 167±9 | 168±10 | 0.65 |
| 167 (IQR 160–170) | 166 (IQR 160–173) | ||
| NYHA FC (n) (I/II/III/IV) | 0/19/65/17 | 1/4/17/0 | 0.033 |
| Logistic euroSCORE (%) | 24.3±14.6 | 7.2±4.7 | <0.0001 |
| Coronary heart disease (n/%) | 51/50% | 9/41% | 0.56 |
| Previous cardiac surgery (n/%) | 25/25% | 1/5% | 0.07 |
| Prior myocardial infarction (n/%) | 25/25% | 2/9% | 0.19 |
| Arterial hypertension (n/%) | 55/54% | 16/73% | 0.18 |
| Diabetes (n/%) | 22/22% | 3/14% | 0.57 |
| Peripheral artery occlusive disease (n/%) | 26/26% | 4/18% | 0.64 |
| Chronic renal insufficiency (n/%) | 31/31% | 2/9% | 0.07 |
| COPD (n/%) | 26/26% | 4/18% | 0.64 |
| PCWP (mm Hg) | 15.6±11.1 | 17.9±7.9 | 0.42 |
| 14.0 (IQR 7.7–22.2) | 16.0 (IQR 12.2–24.0) | ||
| PAP mean (mm Hg) | 28.0±11.5 | 24.4±9.5 | 0.29 |
| 25.5 (IQR 17.0–40.0) | 16.2 (IQR 16.2–31.0) | ||
| PAP peak (mm Hg) | 44.5±18.0 | 42.9±19.3 | 0.76 |
| 39.0 (IQR 30.0–59.0) | 38.0 (IQR 28.7–48.2) |
Data, if appropriate, are presented as mean ± SD and median and IQR. Significant values are printed in bold.
COPD, chronic obstructive pulmonary disease; NYHA FC, New York Heart Association Functional Class; PAP, pulmonary artery pressure; PCWP, pulmonary capillary mean wedge pressure.